ENGOT-ov45/NCRI/ATHENA

Leading group: NCRI

Clinical Trial Study: ATHENA: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment following Response to Front-Line Platinum-Based Chemotherapy

Planned number of patients: 1000

Participating groups:
AGO-De, BGOG, CEEGOG, CTI, GEICO, HeCOG, ISGO, MITO, NSGO, PGOG, TRSGO

Arm	Intervention/treatment
Experimental: Arm A oral rucaparib + intravenous (IV) nivolumab	Drug: Rucaparib Oral rucaparib will be administered twice daily Other Names: • Rubraca • CO-338 Drug: Nivolumab IV nivolumab will be administered once every 4 weeks Other Names: • Opdivo • BMS-936558
Experimental: Arm B oral rucaparib+IV placebo	Drug: Rucaparib Oral rucaparib will be administered twice daily Other Names: • Rubraca • CO-338 Drug: Placebo IV Infusion IV placebo will be administered once every 4 weeks
Experimental: Arm C oral placebo+ IV nivolumab	Drug: Nivolumab IV nivolumab will be administered once every 4 weeks Other Names: • Opdivo • BMS-936558 Drug: Placebo Oral Tablet Placebo tablets will be administered twice daily

Arm	Intervention/treatment
Placebo Comparator: Arm D Oral placebo + IV placebo	Drug: Placebo Oral Tablet Placebo tablets will be administered twice daily Drug: Placebo IV Infusion IV placebo will be administered once every 4 weeks

Primary Outcome Measures:

1. Investigator assessed Progression-free survival (PFS) [Time Frame: From randomization until disease progression (up to approximately 7 years)]

Secondary Outcome Measures:

1 Blinded independent central review (BICR) PFS [Time Frame: Every ~12 weeks after the start of combination treatment for ~3 years, then every ~24 weeks thereafter until disease progression. Study data collection expected to last for ~7 years
2 Overall Survival (OS) [Time Frame: From enrollment to primary study completion of study (up to approximately 10 years)]
3 Objective response rate (ORR) [Time Frame: For patients with measurable disease, every ~12 weeks after the start of combination treatment for ~3 years, then every ~24 weeks thereafter until disease progression. Study data collection expected to last for ~7 years]
4 Duration of response (DOR) [Time Frame: For patients with measurable disease, every ~12 weeks after the start of combination treatment for ~3 years, then every ~24 weeks thereafter until disease progression. Study data collection expected to last for ~7 years]
5 Number of participants with treatment-emergent Adverse Events (AEs) as assessed by CTCAE v4 (or higher) as a measure of safety and tolerability [Time Frame: Collected from the time patient receives first dose of study drug until post treatment safety follow-up period (up to approximately 10 years)]
6 Number of participants with serious AEs as a measure of safety and tolerability [Time Frame: Collected from the time patient receives first dose of study drug until post treatment safety follow-up period (up to approximately 10 years)]
7 Number of participants with laboratory abnormalities as a measure of safety and tolerability [Time Frame: Collected from the time patient receives first dose of study drug until post treatment safety follow-up period (up to approximately 10 years)]

Eligibility Criteria

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	Female

Criteria

Inclusion Criteria:

- Newly diagnosed advanced (FIGO stage III-IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Completed cytoreductive surgery, including at least a bilateral salpingo-oophorectomy and partial omentectomy, either prior to chemotherapy (primary surgery) or following neoadjuvant chemotherapy (interval debulking)

- Completed first-line platinum-based chemotherapy and surgery with a response, in the opinion of the Investigator
- Sufficient tumor tissue for planned analysis
- ECOG performance status of 0 or 1

Exclusion Criteria:

- Pure sarcomas or borderline tumors or mucinous tumors
- Active second malignancy
- Known central nervous system brain metastases
- Any prior treatment for ovarian cancer, other than the first-line platinum regimen
- Evidence of interstitial lung disease or active pneumonitis
- Active, known or suspected autoimmune disease

Condition requiring active systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications